This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letters to the Editor

Reply to “Galantamine and QTc Prolongation”

Matthew W. Nelson, PharmD, BCPP, and Robert W. Buchanan, MD

Published: January 15, 2007

Article Abstract

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

Sir: We appreciate and read with interest the comments by Drs. Brashear and Spivey. In response to our case report,1 they presented unpublished data from 2 studies performed by Johnson & Johnson Pharmaceutical Research and Development: 1 in subjects with schizophrenia and 1 in subjects with Alzheimer’s disease. Because these studies are unpublished, we are unable to evaluate important study sample details, such as subject age and gender, comorbid diseases, and concomitant medications, and therefore cannot comment on the relevance of their results to the case that we presented.

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Volume: 68

Quick Links: Cardiology , Medical

Sign-up to stay
up-to-date today!


Already registered? Sign In

Original Research

Effect of Zuranolone on Concurrent Anxiety and Insomnia Symptoms in Women With Postpartum Depression

Zuranolone was associated with improvements in depressive and anxiety symptoms and was beneficial for insomnia and patient-perceived...